Call for Abstract

2nd International Conference on Pharmaceutical Chemistry, will be organized around the theme “Recent Trends and Advancements in the fields of Pharma and Chemistry”

Pharmaceutical Chemistry 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Pharmaceutical Chemistry 2017

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Physicochemical and biological factors that contribute to drug action
  • Track 1-2Medicinal Radiocompounds or Radiopharmaceuticals
  • Track 1-3Global Pharmaceutical Policy
  • Track 1-4Impurities and Impurity Profile Significance in API
  • Track 1-5Design of Safer Chemicals and Products
  • Track 1-6Process Chemistry Considerations
  • Track 1-7Structure-activity relationships of drug Moiety
  • Track 1-8Synthetic chemistry including combinatorial methods
  • Track 1-9In vivo and in vitro biotransformations of drugs
  • Track 1-10Modelling and designing of small compounds
  • Track 2-1Application of Medicinal Chemistry to Pharmacology
  • Track 2-2Computer aided drug design (CADD): Virtual screening and Molecular modeling
  • Track 2-3High-Throughput Screening
  • Track 2-4Design and application of prodrugs
  • Track 2-5Drug-Receptor complex/Interactions
  • Track 2-6Molecular modification of known drugs
  • Track 2-7Prodrugs Studies
  • Track 3-1Molecular mechanics
  • Track 3-2Discovery of biomolecules through metagenomics
  • Track 3-3Chemical approaches to stem-cell biology
  • Track 3-4Metal complexes in medicine
  • Track 3-5Bioorganic and Bioinorganic Chemistry
  • Track 3-6Synthetic biology
  • Track 3-7Enzymology
  • Track 3-8Genome Analysis
  • Track 3-9Chemical and Molecular dynamics
  • Track 3-10Applications of Chemical Biology in Drug Discovery
  • Track 4-1Hit to lead
  • Track 4-2Lead identification and optimization
  • Track 4-3Chemical biology approach to drug discovery
  • Track 4-4Plant derived drugs in drug discovery
  • Track 4-5Computer aided drug models in drug discovery
  • Track 4-6Drug transporters in drug discovery
  • Track 4-7A novel paradigm of drug discovery
  • Track 4-8Clinical Drug Development
  • Track 5-1In-Silico molecular design software and tools
  • Track 5-2Structure based drug design
  • Track 5-3Ligand-based Drug Design
  • Track 5-4Rational Drug Design
  • Track 5-5De Novo Ligand design
  • Track 5-6Computer-Assisted Drug Design
  • Track 5-7
  • Track 5-8Molecular modelling and drug design
  • Track 5-9Computer graphics in drug design
  • Track 6-1Drug Delivery using Nanotechnology
  • Track 6-2Drug carrier
  • Track 6-3Neural drug delivery systems
  • Track 6-4Acoustic targeted drug delivery
  • Track 6-5Thin film drug delivery
  • Track 6-6Other Controlled Drug Delivery Systems
  • Track 6-7Liposomal and Target Delivery System
  • Track 6-8Beaded Delivery Systems
  • Track 6-9Identification and validation of (emerging) drug targets
  • Track 6-10Strategies for drug delivery to the brain
  • Track 7-1Biosynthetic Mechanisms
  • Track 7-2Prostaglandins and Steriods
  • Track 7-3 Alkaloids and Terpenes
  • Track 7-4Synthesis of Amino Acids
  • Track 7-5Peptides & Proteins
  • Track 7-6The Primary Structure of DNA
  • Track 7-7The Secondary & Tertiary Structures of DNA
  • Track 7-8RNA and Protein Synthesis
  • Track 7-9Isolation and Structural elucidation of Natural Products
  • Track 8-1Molecular Biotechnology: From DNA Sequence to Therapeutic Protein
  • Track 8-2Production and Purification of Recombinant Proteins
  • Track 8-3Immunogenicity of Therapeutic Proteins
  • Track 8-4Economic Considerations in Medical Biotechnology
  • Track 8-5Monoclonal Antibodies in Various Diseases
  • Track 8-6Biomolecules used to develop targeted drug therapies
  • Track 8-7Biomolecules that elicit specific ligand-receptor interactions
  • Track 8-8Oligopeptides and Nucleic acids
  • Track 8-9Design of proteins
  • Track 9-1Generating human proteome antibodies via phage display and directed evolution
  • Track 9-2Classical or Quantum mechanic
  • Track 9-3Probing and modulating membrane proteins
  • Track 9-4De novo design of catalytic and membrane proteins
  • Track 9-5Creating fluorescent probes targeting the genome and key bio-pathways
  • Track 9-6Investigating cellular interactions in tissues
  • Track 9-7Globally analyzing and dissecting apoptosis
  • Track 9-8Proximity tagging of protein-protein interactions
  • Track 9-9Monitoring enzyme activity and disease biomarkers
  • Track 9-10
  • Track 10-1The Metrics of Green Chemistry
  • Track 10-2Green Chemistry and Sustainability
  • Track 10-3Designing Sustainable Solutions
  • Track 10-4Principles Applied in Green Chemistry
  • Track 10-5Green Chemistry Focuses on Inherent Hazards
  • Track 10-6Green Chemistry Tackles the Grand Challenges
  • Track 10-7Adverse Effects of Chemicals on Health and the Environment
  • Track 10-8Green Chemistry Problems
  • Track 11-1Catalyst: Acid and Base Catalyzed Reactions
  • Track 11-2Characterization of inorganic compounds
  • Track 11-3Reactions at ligands
  • Track 11-4Redox reactions
  • Track 11-5Transition Metal Catalysis
  • Track 11-6Free-Radical Reactions
  • Track 11-7Molecular Rearrangements
  • Track 11-8Electrophilic and Nucleophilic Substitution
  • Track 11-9Organometallic Reagents and Compounds
  • Track 11-10Synthetic inorganic chemistry
  • Track 12-1Nomenclature of Heterocyclic Chemistry
  • Track 12-2Six-Membered Heterocycles: Synthesis and its Activity
  • Track 12-3Five-Membered Heterocycles: Synthesis and its Activity
  • Track 12-4Four-Membered Heterocycles: Synthesis and its Activity
  • Track 12-5Three-Membered Heterocycles: Synthesis and its Activity
  • Track 12-6General Strategies for Heterocycle Synthesis
  • Track 12-7Reations involved in Heterocyclic chemistry
  • Track 12-8Functional Group Chemistry
  • Track 12-9Classification of Heterocyclic Chemistry
  • Track 12-10Some Polycyclic Heterocycles Compounds: Synthesis and its Activity
  • Track 13-1Design, manufacture and use of efficatious dosage forms
  • Track 13-2Types of Formulation: Enteral, Parenteral and Topical
  • Track 13-3Water-miscible formulations
  • Track 13-4Other formulations
  • Track 13-5Pesticide formulation
  • Track 13-6Recent Developments in Dosage Form Design
  • Track 13-7Establishing the Bioequivalence of Pharmaceutical Products
  • Track 14-1Nanobiopharmaceutics
  • Track 14-2Synthesis of Vaccines, blood and blood components
  • Track 14-3Recombinant therapeutic protein, and living cells used in cell therapy
  • Track 14-4Large-scale production: Transgenics
  • Track 14-5Allergenics and somatic cells
  • Track 14-6Biologics: Sugars, proteins, or nucleic acids
  • Track 14-7Medical devices
  • Track 15-1Various Separation Techniques
  • Track 15-2Electroanalytical methods: Potentiometry and voltammetry
  • Track 15-3Spectroscopy: UV, Mass Spectroscopy and other Spectroscopies techniques
  • Track 15-4NMR Spectroscopy
  • Track 15-5Chromatography techniques
  • Track 15-6Radioanalytical chemistry
  • Track 15-7Gravimetric analysis
  • Track 15-8UPLC and HPLC
  • Track 15-9Titrimetry and X-ray Crystallography
  • Track 16-1Pharmaceutical Processing Equipment
  • Track 16-2Pharmaceutical Machinery: Tableting, Tube Filling, Liquid Filling, Labeling
  • Track 16-3Pharmaceutical Machinery: Cartoning and Packaging
  • Track 16-4Pharmaceutical Machinery: Standards
  • Track 16-5Pharmaceutical Machinery: Technology
  • Track 16-6Pharmaceutical Manufacturing Equipment
  • Track 16-7Laboratory & Quality Control Equipment
  • Track 16-8Pharmaceutical Machinery: Global Market
  • Track 17-1Pharmacological in vitro and in vivo investigations
  • Track 17-2Toxicology and Pharmacogenomics
  • Track 17-3Biomolecular Interactions and Thermodynamic
  • Track 17-4Bioassay and Dose effect relationships
  • Track 17-5Drug-receptor interactions on the molecular level
  • Track 17-6Drug Transport across Biological Membranes
  • Track 17-7Various ScreeningMethods
  • Track 17-8Enzyme Inhibitors
  • Track 17-9Cancer Therapy

Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials and biological devices, to Nano electronic biosensors, and even possible future applications of molecular nanotechnology such as biological machines. Using nanoparticle contrast agents, images such as ultrasound and MRI have a favorable distribution and improved contrast. This might be accomplished by self assembled biocompatible Nano devices that will detect, evaluate, treat and report to the clinical doctor automatically. Nanotechnology ("nanotech") is manipulation of matter on an atomic, molecular, and supramolecular scale. The earliest, widespread description of nanotechnology referred to the particular technological goal of precisely manipulating atoms and molecules for fabrication of macro scale products, also now referred to as molecular nanotechnology. A more generalized description of nanotechnology was subsequently established by the National Nanotechnology Initiative, which defines nanotechnology as the manipulation of matter with at least one dimension sized from 1 to 100 nanometers.

Clinical pharmacy is the branch of pharmacy in which pharmacists provide patient care that optimizes the use of medication and promotes health, wellness, and disease prevention. Clinical pharmacists care for patients in all health care settings but the clinical pharmacy movement initially began inside hospitals and clinics. Clinical pharmacists often work in collaboration with physicians, nurse practitioners, and other healthcare professionals. Provide a consistent process of patient care that ensures the appropriateness, effectiveness, and safety of the patient’s medication use. Consult with the patient’s physician(s) and other health care provider(s) to develop and implement a medication plan that can meet the overall goals of patient care established by the health care team. Clinical pharmacists practice in many different health care environments: hospitals and their affiliated outpatient clinics, emergency departments, community pharmacies, physicians’ offices, community-based clinics, nursing homes, and managed care organizations.